A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The company to receive upfront and milestone payments, in addition to royalties
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Substantial reduction in losses
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
This work has been published in the journal ‘ACS applied materials and interface’
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
With the acquisition of these further shares, TWPL has now become company's subsidiary.
Subscribe To Our Newsletter & Stay Updated
